NCT03432949View on ClinicalTrials.gov

Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 23, 2018

Primary Completion Date

September 30, 2023

Study Completion Date

July 30, 2024

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

Dexamethasone plus Radium-223

Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.

Trial Locations (1)

Unknown

University Health Network, Toronto

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University Health Network, Toronto

OTHER